Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temodar Plus O6-Benzylguanine in Temodar-Resistant Malignant Glioma
NCT00613093Phase 2Completed
- Sponsor
- Duke University
- Start
- Oct 2002
- Primary completion
- Mar 2006
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of 6-benzylguanine in malignant glioma, glioblastoma multiforme (GBM) and anaplastic glioma (2 arms), sponsored by Duke University. Primary endpoint: Radiographic evidence of tumor response at 6 months. Started Oct 2002; status: completed.
02
Drugs
6-benzylguanine
03
Conditions
malignant gliomaglioblastoma multiforme (GBM)anaplastic glioma
Beyond the preview
Go deeper on NCT00613093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00613093.